Analysis of the evolution of drug registration and management policies in China from the perspective of policy toolsZHU Jun-cheng, WANG Shu-ling449-456
Comparison of equal value of life years gained and quality-adjusted life-year as health outcome measuresHU Zhao, LIU Yong-jun457-464
New quality productivity empowers the high-quality development of the pharmaceutical industry:theoretical logic and practical pathSUN Qi, LI Yong465-472
Advancements in pharmaceutical co-crystal research and key considerationsPAN Jing, HUANG Xiao-long477-482
Advances in protein kinase B inhibitor capivasertib for breast cancer treatmentGENG Ji-hong, QUAN Xiang-hua, ZHAO Jun, DU Cai-ying, SUN Cai-hong, YUAN Hai-dan483-489
Ensartinib treatment for REV1-ALK/EML4-ALK complex ALK fusion lung adenocarcinoma:a case reportZHANG Chang-gong490-493
Clinical significance of serum levels of total cholesterol,high-density lipoprotein and lipoprotein(a)in the prognosis of colorectal cancerPAN Ru-yan, WANG Yue, ZHU Qi, LU Yi, XIAO Yao494-497
Analysis of civil liability and risk response to adverse event disputes in drug clinical trialsZHAO Tian-jiao, DENG Yong498-504
Discussion on the rights of subjects after termination of clinical trials for anticancer drugsYANG Feng, YANG Wan-shuang, GONG Qian505-510